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Abstract
Background: Pregnancy in women with systemic lupus erythematosus (SLE) or antiphospholipid antibodies (APL Ab)—
autoimmune conditions characterized by complement-mediated injury—is associated with increased risk of preeclampsia
and miscarriage. Our previous studies in mice indicate that complement activation targeted to the placenta drives
angiogenic imbalance and placental insufficiency.
Methods and Findings: We use PROMISSE, a prospective study of 250 pregnant patients with SLE and/or APL Ab, to test the
hypothesis in humans that impaired capacity to limit complement activation predisposes to preeclampsia. We sequenced
genes encoding three complement regulatory proteins—membrane cofactor protein (MCP), complement factor I (CFI), and
complement factor H (CFH)—in 40 patients who had preeclampsia and found heterozygous mutations in seven (18%). Five
of these patients had risk variants in MCP or CFI that were previously identified in atypical hemolytic uremic syndrome, a
disease characterized by endothelial damage. One had a novel mutation in MCP that impairs regulation of C4b. These
findings constitute, to our knowledge, the first genetic defects associated with preeclampsia in SLE and/or APL Ab. We
confirmed the association of hypomorphic variants of MCP and CFI in a cohort of non-autoimmune preeclampsia patients in
which five of 59 were heterozygous for mutations.
Conclusion: The presence of risk variants in complement regulatory proteins in patients with SLE and/or APL Ab who
develop preeclampsia, as well as in preeclampsia patients lacking autoimmune disease, links complement activation to
disease pathogenesis and suggests new targets for treatment of this important public health problem.
Study Registration: ClinicalTrials.gov NCT00198068
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Preeclampsia complicates 4%–5% of all pregnancies worldwide,
causing significant maternal and neonatal mortality, and claims
the lives of .60,000 mothers each year in developing countries
[1]. Although typically diagnosed with the onset of hypertension
and proteinuria after 20 weeks’ gestation, the syndrome begins
earlier in pregnancy with abnormal placental development. The
specific ‘‘anatomical’’ defect, the failure of uterine spiral arteries to
remodel into dilated, flaccid vessels, leads to underperfusion of the
intervillous space and placental hypoxia. The clinical manifesta-
tions of preeclampsia represent the maternal response to an excess
of antiangiogenic factors released by the hypoperfused placenta.
These factors include vasculopathic factors such as soluble fms-like
tyrosine kinase 1 (sFlt-1), a potent vascular endothelial growth
factor (VEGF) antagonist, and soluble endoglin, an inhibitor of
TGF-b signaling [2,3]. Disease manifestations range from mild
blood pressure elevations to severe hypertension, the HELLP
syndrome (hemolysis, elevated liver enzymes, and low platelets), or
eclampsia (seizures). The molecular basis for placental dysregula-
tion is unknown and treatment is limited. Higher rates of
preeclampsia in sisters, daughters, and mothers of affected women
suggests a genetic contribution to risk for disease, and evidence for
paternal components of predisposition supports the hypothesis that
the genotype of the fetus contributes to the overall risk of
preeclampsia [4].
Immunologic maladaption has been proposed as a pathogenic
mechanism for preeclampsia, but remains an unproven theory.
We have previously established a link between the complement
system and angiogenic factor imbalance associated with placental
dysfunction (Figure 1). Studies in mouse models of pregnancy
indicate that complement activation targeted to the placenta drives
angiogenic imbalance, placental insufficiency, and endothelial
injury [5]. In our experimental model, complement C5a-C5a
receptor interactions trigger release of sFlt-1. This antiangiogenic
factor is associated with hypertension, proteinuria, and glomerular
endotheliosis in rodents [2,3,6] and is elevated in the circulation of
pregnant women destined for preeclampsia. Further, in mice with
abnormal pregnancies, the alternative complement pathway
amplifies fetoplacental injury [5]. Also, uncontrolled complement
activation due to deficiency of a membrane complement regulator
analogous to human MCP is embryonic lethal because of maternal
complement-triggered damage, and pregnancies are rescued in
mice with reduced alternative pathway function [7]. Elevated
levels of the alternative pathway complement activation fragment
Bb in the first 20 weeks of pregnancy was recently found to be
independently associated with preeclampsia later in pregnancy [8]
and underscores the importance of complement, particularly the
alternative pathway, in this syndrome.
Pregnancy in women with systemic lupus erythematosus (SLE)
or the antiphospholipid syndrome (APS), two autoimmune
diseases characterized by complement-mediated injury, is associ-
ated with an increased risk of preeclampsia, placental insufficiency,
fetal growth restriction, and miscarriage [9]. In these patients,
autoantibodies targeted to the placenta initiate local complement
activation which, if unabated, leads to abnormal placental
development (Figure 1). Indeed, complement activation products
have been demonstrated in deciduas, chorionic villi, and vessel
walls in the placentas of patients with APL Ab and in patients with
preeclampsia [10,11]. Moreover, evidence of alternative pathway
activation has been found in the circulation of pregnant SLE
patients. In normal pregnancies, excessive complement activation
is prevented by complement regulatory proteins that are highly
expressed on trophoblast membranes (membrane cofactor protein
[MCP (CD46)], decay accelerating factor [DAF (CD55)], and
CD59) as well as circulating complement regulatory proteins
(complement factor H [CFH], C4b binding protein, and
complement factor I [CFI]) (Figure 1) [11]. We hypothesized that
impaired capacity to limit complement activation predisposes
pregnant women with SLE or APL Ab to preeclampsia.
Loss-of-function mutations in CFH, MCP, and CFI or gain-of-
function mutations in complement components factor B and C3
lead to undesirable complement activation in patients with atypical
hemolytic uremic syndrome (aHUS), a microangiopathy charac-
terized by microvascular endothelial activation, cell injury, and
thrombosis [12,13,14,15]. Complement dysregulation (specifically,
enhanced function of the alternative pathway) contributes to the
pathology of aHUS, a disease associated with glomerular
endothelial cell injury and microthrombi, not unlike the pathologic
findings in preeclampsia, APS, and SLE. Complement mutations in
aHUS demonstrate incomplete penetrance (,50%), indicating that
additional genetic and environmental factors are required to
manifest disease. Pregnancy, SLE, and/or APL Ab may provide
these additional factors. The aims of this study are to translate our
findings in mouse models to patients and determine whether
variations in complement regulatory proteins leading to impaired
Figure 1. Complement activation in preeclampsia. Black and blue
arrows indicate triggering of complement cascades by autoantibodies
or damaged self-tissue; green arrows, deposition of C3b on a target sets
in motion the powerful amplification loop of the alternative pathway;
red arrows, effector activities of complement are generated by C3b
deposition and C3a release and the downstream mediators C5b-9 and
C5a. Regulation of feedback loop of alternative pathway on the
placental trophoblasts (or endothelial cells) occurs through limited
proteolytic cleavage of C3b to generate iC3b. This reaction is carried out
by a serine protease, factor I (FI), along with membrane cofactor protein
(MCP) or CFH (FH). Because SLE and APS are characterized by
autoantibodies that trigger the classical pathway, defective regulation
of C4b (a component of the classical pathway C3 convertase) by MCP is
also likely to influence the severity of tissue injury and risk for
preeclampsia. If regulators such as MCP, CFI (FI), or CFH (FH) are
dysfunctional, excessive complement activation occurs. This may result
in placental damage, thrombobosis and release of antiangiogenic
factors, culminating in preeclampsia.
doi:10.1371/journal.pmed.1001013.g001
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or APL Ab and whether such variants are also present in women
who develop preeclampsia in the absence of autoimmune disease.
Methods
Participants
The first group of patients studied were enrolled in The
PROMISSE Study (Predictors of pRegnancy Outcome: bioMark-
ers In antiphospholipid antibody Syndrome and Systemic lupus
Erythematosus), a prospective multi-center observational study to
identify predictors of pregnancy outcome initiated in 2003.
Patients with SLE (defined as $4 ACR criteria) and/or APL Ab
(defined as at least one of following documented twice between
6 wk and 5 y apart: ACL [IgG or IgM $40 units], lupus
anticoagulant, or anti-b2GPI [IgG or IgM $40 units]) and disease
controls were recruited by 12 wk gestation. At screening, patients
with renal disease (proteinuria .1,000 mg/24 h, RBC casts, or
serum creatinine .1.2 mg/dl), taking prednisone .20 mg/d,
diabetes mellitus (Type I and Type II antedating pregnancy),
hypertension (blood pressure $140/90 mmHg), or multiple
gestations were excluded. Detailed medical and obstetrical
information and serial blood specimens were obtained monthly
during the course of pregnancy. Preeclampsia was defined as new
onset of elevated systolic blood pressure ($140 mmHg) and/or
elevated diastolic blood pressure ($90 mmHg) after 20 wk
gestation on two occasions at least 4 h apart and proteinuria of
300 mg or greater in a 24 h urine specimen or $1+ on dipstick at
least 4 h apart in the absence of pyelonephritis or hematuria.
Severe preeclampsia and HELLP are defined by standard criteria
[16]. In women with proteinuria present in early gestation,
preeclampsia was defined as an increase in proteinuria to double
their baseline level. For patients with a history of preeclampsia in
previous pregnancies, medical charts were reviewed to document
that patients met the above criteria above.
Of 250 enrolled patients with SLE and/or APL Ab who
completed their pregnancies before 31 May 2008, 30 patients
developed preeclampsia during the study and 10 additional
patients had documented preeclampsia in a previous pregnancy
(Table 1). Three of the 30 patients with preeclampsia during the
PROMISSE Study pregnancy had documented preeclampsia in a
previous pregnancy. None of the disease-free controls developed
preeclampsia. The racial/ethnic distribution of the 40 patients
with preeclampsia was 67% white, 17% black, 7% Asian, 5%
Hispanic, and 4% other.
The Institutional Review Board at each of the PROMISSE
Study sites (Hospital for Special Surgery, NY, NY, US; NYU
School of Medicine, NY, NY, US; Johns Hopkins University,
Department of Rheumatology, Johns Hopkins Medical Institu-
tions, Baltimore, MD, US; Mount Sinai Hospital, Toronto,
Canada; University of Utah, Intermountain Health Care, Salt
Lake City, UT, US; Oklahoma Medical Research Foundation,
University of Oklahoma Health Sciences Center, Oklahoma City,
OK, US) gave approval for human participation for patients.
Written informed consent that included the use of material for
genetic research was obtained from all PROMISSE participants
who contributed samples toward this study. All study samples were
deidentified.
The second group of patients studied was from the Universal
Samples Database at University of Utah, which stores maternal
blood and clinical data from women who present to labor and
delivery. Charts were reviewed to confirm the diagnosis of severe
preeclampsia and HELLP defined according to established
criteria, and 59 patients meeting criteria and with available
DNA were identified [16]. The racial/ethnic distribution of
patients with severe preeclampsia and/or HELLP was 74% white
(non-Hispanic), 25% Hispanic, and 1% other. Control pregnan-
cies defined as uncomplicated term deliveries in women with no
more than one pregnancy loss and at least one live birth were
identified in the Universal Samples Database at University of
Utah. The Institutional Review Board at University of Utah, Salt
Lake City, UT, gave approval for human participation for the
participants whose samples are stored at the Universal Samples
Database at University of Utah. Samples from 143 ethnically
matched controls were available.
The allele frequency of MCP A304V and CFI IVS12+5G .T
variants in white individuals were determined using DNA from
The UK Blood Services collection of Common Controls (UKBS
collection) which forms part of the Wellcome Trust Case Control
Consortium (WTCCC) (http://www.wtccc.org.uk) [17,18].
Genetic and Statistical Analyses
Genomic DNA was extracted from peripheral blood leukocytes,
and coding sequence and intronic flanking regions of MCP, CFH,
and CFI were screened as described [19,20]. Mutations considered
for our analysis were either missense or nonsense coding mutations
and mutations in conserved positions of splice sites and promoters.
To further restrict our study to mutations that are likely
deleterious, we ignored mutations present in dbSNP (http://
www.ncbi.nlm.nih.gov/projects/SNP/), except for those previous-
ly observed in aHUS. This left novel variants and known aHUS
alleles with the described properties. Mutations that occur in less
than 5% of the population are termed low-frequency variants, and
those in ,0.5% are rare variants [21].
The rare variants could not be tested for Hardy-Weinberg
equilibrium (HWE) because they do not appear in controls. The
A304V variant was tested and found to be in HWE in 40
PROMISSE and 59 Utah cases (p=1.0) and in the WTCCC
Table 1. Preeclampsia in autoimmune PROMISSE patients.
Clinical Characteristics No. Enrolled
No. with Preeclampsia
in PROMISSE
No. with Preeclampsia
in Previous Pregnancy
a
Total Patients with
Preeclampsia
b
% Patients with
Preeclampsia
SLE only 149 19 5 23 15%
APL Ab only 59 6 5 10 17%
SLE with APL Ab 32 5 3 7 22%
Total 250 30 13 40 17%
aThe PROMISSE Study pregnancy was the first pregnancy in 40% of the SLE patients (with and without APL Ab) and in 9% for APL Ab patients without SLE. The APL Ab
patients differed from SLE patients with regard to multiparity because pregnancy loss is a criterion for testing for APL Ab.
bThree patients had preeclampsia in the PROMISSE Study and also had preeclampsia in previous pregnancies.
doi:10.1371/journal.pmed.1001013.t001
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assessed for HWE because no alleles were present, and the 143
Utah controls were found not to be in HWE, largely because of a
single homozygote that was sampled (p=0.02).
To test the hypothesis that A304V is associated with pree-
clampsia, we combined cases and controls from the PROMISSE
and Utah studies. These two populations were combined because
the frequencies of A304V were similar, and Fisher’s exact test was
used to test for enrichment of a deleterious, dominant allele.
Expression and Functional Assessment of MCP
Substitution mutagenesis was performed using the QuikChange
site-directed mutagenesis kit (Stratagene). The MCP template was
the MCP isoform BC1 (GenBank accession no. X59405) cloned
into the EcoRI site of plasmid pCDNA3.1+ (Stratagene).
Transient transfections were performed with Fugene-6 (Roche
Molecular Biochemicals) into Chinese hamster ovary (CHO) K1
cells. After cell lysis, MCP was quantified in an ELISA as
described [22]. Briefly, MCP mAb GB24 was coated at 2.5 mg/ml
on microtiter wells followed by blocking in PBS containing 4%
BSA and 0.05% Tween 20. Cell lysates and standards were
incubated in wells followed by reaction with a rabbit anti-MCP
antiserum, horseradish- peroxidase–labeled donkey anti-rabbit
IgG (Jackson ImmunoResearch), and ImmunoPure TMB Sub-
strate kit (Pierce).
Ligand binding and cofactor assays for C4b and C3b have been
described [22]. Briefly, an ELISA format was used for character-
izing ligand binding. C3b or C4b (Complement Technologies) was
coated onto wells of a microtiter plate. Next, dilutions of MCP
wild-type or mutant CHO lysates were added. Cofactor assays
employed biotinylated ligands in low- or physiologic salt buffer
(i.e., 10 mM Tris [pH 7.4], with 25 or 150 mM NaCl), CFI
(100 ng), and cell lysates (25 pg of wild-type or mutant MCP).
After 20 and 90 min, cleavage fragments were analyzed by a 10%
size fractionation on reducing SDS/PAGE followed by transfer,
Western blotting, and densitometric scanning [22].
Results
Patients with Preeclampsia
The PROMISSE Study is a prospective multi-center observa-
tional study in which patients with SLE and/or APL Ab were
enrolled at 12 wk gestation and followed through pregnancy.
Patients with renal insufficiency, diabetes mellitus (antedating
pregnancy), hypertension, or multiple gestations (risk factors
predisposing to preeclampsia) were excluded. Between 2003 and
2008, 250 patients with SLE and/or APL Ab completed their
pregnancies, 40 of whom developed preeclampsia during the study
or had preeclampsia in a previous pregnancy (Table 1). All
patients with preeclampsia were screened for mutations in the
genes encoding the complement regulatory proteins MCP, CFI,
and CFH. Mutations that occur in less than 5% of the population
(low-frequency alleles) are termed uncommon variants [21].
We identified heterozygous mutations in complement system
pathway genes in seven of 40 patients with preeclampsia (18%)—
four patients with mutations in MCP, two with CFI mutations,
and one with a CFH mutation. Complement C3 levels were
normal at enrollment in these patients. We did not find any
mutations in 34 patients without preeclampsia (15 matched for
disease [SLE and/or APL Ab], age, and ethnicity, and 19 healthy
control patients matched for age and ethnicity) (7/40 versus 0/34,
p,0.01; also see results of mutation screening described for each
gene in the sections to follow). We reject the null hypothesis of
equal or fewer rare, deleterious alleles in controls at the 0.02 level
(p=0.0105 for the one-tailed test). This approach represents a
variation of existing collapsing methods for the analysis of low-
frequency variants [23]. The frequency of these mutations and
variants in other healthy populations is described below. The
clinical characteristics of patients with mutations are presented in
Table 2.
To replicate the relationship of complement system variants
with preeclampsia and to determine whether mutations in
complement regulatory proteins are present in non-autoimmune
patients with severe preeclampsia and/or HELLP, we screened 59
patients and 143 ethnically matched healthy controls with normal
pregnancies from the Universal Samples Database at the
University of Utah for mutations in MCP, CFI, and CFH. We
identified heterozygous mutations in the genes of five patients—
four in MCP and one in CFI. No significant sequence variants
were detected in CFH. The clinical characteristics of the patients
from this cohort are presented in Table 3. Three individuals
among the healthy controls had the A304V variant (5/59 versus
3/143, p,0.05). Details of the mutations and variants and their
distribution are described below.
Mutations and Variants of MCP
MCP is a widely expressed transmembrane protein that binds
C3b and C4b deposited on cell surfaces and serves as a cofactor
for their cleavage by CFI. The resulting attached fragments, iC3b
and C4d, are not capable of forming convertases. By cleaving C3b,
MCP is a key regulator on host cells of the amplification loop of
the alternative pathway. Four patients with preeclampsia (10%)
had mutations in MCP. Three patients were heterozygous for
MCP A304V, a low-frequency hypomorphic variant previously
shown to be deficient in control of alternative pathway activation
on the cell surface [14]. The allele occurred at a frequency of 3.7%
in the PROMISSE Study patients with preeclampsia. All three
patients with A304V were white, and one had SLE only, one APL
Ab only, and one both SLE and APL Ab. Two patients had severe
preeclampsia and two patients reported prior pregnancy compli-
cations, including preeclampsia (Table 2). This variant has been
identified in four of 238 patients from the French multi-center
aHUS cohort and in two of 181 healthy French controls, and in
none of 120 white participants from another study [12]. Because
the frequency of MCP A304V was not reported in publically
available databases, including HapMap, we genotyped a large
population of whites. In 1,529 individuals from the WTCCC, the
allele frequency was 2.1% (61 heterozygotes and two homozy-
gotes). Of note, no pregnancy histories or other medical
information was available for these individuals.
We confirmed the association of MCP A304V with preeclamp-
sia in a second cohort identified from the Universal Samples
Database at the University of Utah. In 59 non-autoimmune
patients with severe preeclampsia and/or HELLP, we identified
four individuals (6.8% of patients) heterozygous for MCP A304V
(allele frequency 3.4%). The details of their pregnancies are
presented on Table 3. In 144 ethnically and geographically
matched controls with uncomplicated pregnancies, two individuals
were heterozygous and one homozygous for MCP A304V (allele
frequency 1.4%), none of whom had histories of thrombotic
microangiopathy or preeclampsia. The frequency of MCP A304V
was consistent with our findings in the WTCCC. Combining our
autoimmune and non-autoimmune cohorts with preeclampsia
(n=99), we identified seven individuals heterozygous for MCP
A304. In both groups separately and when combined (99 cases
versus 178 controls), A304V confers risk of preeclampsia. The
variant acts in a dominant fashion with an odds ratio of 4.4 (95%
confidence interval 1.1–17.6; p=0.027).
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profile of A304V employing permanent CHO cell lines expressing
an equal copy number of wild-type or A304V. While there was no
detectable difference in ELISA type assays of solubilized protein,
in situ the A304V was ,50% as effective at controlling C3b
deposition by the alternative pathway [14]. In addition, a 25%–
50% reduction in levels of wild-type complement regulatory
proteins expressed by CHO cells impairs regulation of the
alternative pathway, showing that haploinsufficiency has function-
al consequences [14,24].
The potential role of complement dysregulation in preeclamp-
sia is underscored by our discovery of a novel mutation in exon 2
of the gene encoding MCP (K32N) in a patient from the
PROMISSE Study who had SLE. Her pregnancy ended with
preeclampsia and fetal death at 25 wk. She had a history of two
early pregnancy losses. MCP K32N is a missense mutation that
alters a charged solvent-exposed amino acid in complement
control protein repeat (CCP) 1 [25]. To examine its functional
consequences, the K32N mutant construct was transiently
transfected in CHO cells. The mutant protein was quantified
in cellular lysates and binding to human C4b and C3b was
assessed (Figure 2A). While binding to C3b was similar to wild-
type MCP, the mutant showed an approximately 50% decrease
in C4b binding (p,0.001) compared to wild-type MCP. Given
the lower binding to C4b, we suspected that the K32N mutant
form of MCP would have a decreased capacity to serve as a
cofactor for CFI-mediated cleavage of C4b. To examine this
possibility, we performed cofactor assays comparing the ability of
wild-type MCP and rare mutant K32N to serve as cofactors for
cleavage of C3b and C4b by monitoring loss of the a9 chain and
generation of cleavage fragments (C4d in the case of C4b and a1
in the case of C3b) (Figure 2B) [24]. As predicted by the binding
studies, cofactor activity for C3b was similar for the K32N
mutant and wild-type MCP, whereas the K32N mutant showed
decreased CFI-mediated cleavage activity for C4b. At 20 min in
the C4b cofactor activity assay, no C4d was detected in the
K32N lane, but an easily discernable band in wild-type MCP.
We performed densitometric scanning of the C4d after 90 min
and found that cleavage of C4b to C4d in wild-type was four
times greater than in the K32N mutant (Figure 2C). Our results
define the functional defect in K32N and identify the initial
disease-related mutation in MCP that results exclusively in
impaired ability to bind C4b and mediate C4b cofactor activity.
Because SLE is characterized by autoantibodies that trigger the
classical pathway, defective regulation of C4b is likely to
influence the severity of tissue injury and risk for preeclampsia
(Figure 1). Indeed, the presence of C4 degradation products in
placentas from patients with APL Ab and in kidneys from
Table 2. Clinical characteristics of autoimmune patients with complement regulatory protein mutations.
Mutation/Variant Autoimmune Disease GA at Delivery (wk) Other Pregnancies
MCP/A304V SLE 35.4
a 3 early losses, 1 live birth
MCP/A304V SLE, APL Ab 29.0
b None
MCP/A304V APL Ab 37.3 2 live births, 1 with preeclampsia
MCP/K32N SLE 25.0 2 early losses, 1 live birth
CFI/IVS12+5G .T APL Ab 29.0
c 1 live birth, preterm at 24 weeks
CFI/IVS12+5G .T SLE 37.5 1 miscarriage; 1 elective termination
CFH/S40A SLE 37.4 None
Patients were white, except the patient with MCP K32N, who was black. Characteristics of preeclampsia [16].
aSevere preeclampsia with visual disturbance.
bPreeclampsia with oligohydramnios and intrauterine growth restriction (,5th percentile).
cSevere preeclampsia, HELLP syndrome.
GA, gestational age.
doi:10.1371/journal.pmed.1001013.t002
Table 3. Clinical characteristics of non-autoimmune preeclampsia patients with complement regulatory protein mutations.
Mutation/Variant Maternal Age (y) Preeclampsia GA at Delivery (wk)
Fetal Weight in Grams
(Percentile weight for GA)
MCP/A304V 24 Severe 33 2,102 (27)
MCP/A304V 23 Severe
a 34 2,807 (48)
MCP/A304V 41 HELLP
b 22 Neonatal demise
MCP/A304V 33 Severe
c 33 2,013 (22)
CFI/I398L 24 Severe
d 37 2,940 (35); 2,145 (2)
All patients were white.
aPrevious pregnancy preeclampsia delivered at 36 wk.
bPregnancy complicated by sphenoid sinus thrombosis; thrombophilia evaluation negative; four normal previous pregnancies; history of idiopathic thrombocytopenia
purpura; mother with SLE.
cOligohydramnios.
dTwins.
GA, gestational age.
doi:10.1371/journal.pmed.1001013.t003
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pathogenesis [10,26].
Mutation in CFI
CFI, a plasma glycoprotein, is a serine protease that cleaves the
a9 chain of C3b and C4b in the presence of a cofactor protein,
such as CFH or MCP. Inactivation of C3b and C4b prevents the
formation of C3 and C5 convertases and thereby down-modulates
the classical, lectin, and alternative pathways. We found identical
heterozygous mutations in the gene encoding CFI in two unrelated
white women with preeclampsia in the PROMISSE Study
(Table 2). Similar to three of the four patients with MCP variants,
those with CFI mutations had a history of previous pregnancy
complications, specifically preterm deliveries at 24 and 28 wk,
respectively. The mutation identified in CFI, an IVS12+5G .T
change, has been reported in patients with aHUS and was shown
to affect the donor site of intron 12 reducing the splice score from
93 to 86 [27] but did not alter CFI serum levels [12]. The CFI
IVS12+5G .T variant has been identified in six of 325 French
control individuals (0.9% allele frequency) and in eight of 238
patients from the French multi-center aHUS cohort (1.7% allele
frequency) (alone in four patients and in association with a second
mutation in four cases; V. Fremeaux-Bacchi, unpublished results).
The frequency of this variant is not reported in publically available
databases. Our findings suggest that CFI IVS12+5G .T is a low-
frequency variant that may be enriched in aHUS. Its clinical
impact cannot be assessed in the control patients because
pregnancy histories and other medical information were not
available for these individuals.
The two patients presented here and other patients with the
IVS12+5G .T variant have had normal CFI levels (66 and 63
mg/l, nl 42-78 mg/l), but CFI levels within the normal range does
not exclude alterations in local production [28,29]. In the 12
Eutherian mammals that have a similar CFI gene architecture to
human CFI (Ensemble release 52), conservation is perfect at the
+5 intron position. The lack of variation at this position relative to
the surrounding bases argues that a G at this base is functionally
important.
We screened CFI in 57 non-autoimmune patients with severe
preeclampsia and/or HELLP in our second cohort from the
Universal Samples Database at University of Utah. In one patient,
we identified a heterozygous nonsynonymous sequence variant in
exon 11 (c.1246A.G, p.Ile398Leu). We did not find this change
in 117 white British controls. Bienaime et al. and Sellier-Leclerc et
al. have previously demonstrated this variant in three aHUS
patients (two heterozygous, one homozygous) but not in 100
controls [29,30]. CFI was undetectable in the individual with the
homozygous change [29]. Recombinant expression of the I398L
mutant confirmed nearly complete absence of production
compared to wild-type CFI, which was associated with altered
subcellular localization detected by immunofluorescence and
altered endoglycosidase H digestion [29]. We identified two other
nonsynonymous changes in this cohort: c. 1217G.A, p.Ar-
g388His [19,28] and c.1322A.G, p.Lys423Arg [rs41278047].
Both changes have previously been described in control popula-
tions and are classed as SNPs in our study. Identification of CFI
I398L mutation, a complete loss of function leading to
haploinsufficiency, supports a role for defects in complement
regulation by CFI in the pathogenesis of preeclampsia. This
association also suggests that enrichment of IVS12+5G.T
variants in patients with preeclampsia and aHUS [12] is
functionally important, although its mechanism is as yet
undefined.
Mutations in Factor H
The single factor H mutation (S40A) in the PROMISSE cohort
was extensively investigated and not shown to have a functional
defect (normal secretion in a transfection system, normal plasma
levels, and normal to increased C3b binding and cofactor activity)
(unpublished data). No factor H mutations were found in the Utah
cohort.
Discussion
MCP and CFI mutations are, to our knowledge, the first genetic
defects to be associated with preeclampsia in pregnant patients
with SLE and/or APL Ab. Our hypothesis—that mutations
affecting function (missense, nonsense, and conserved splice site
and promoter mutations) in negative regulators of the amplifica-
tion loop of complement would be enriched in preeclampsia as
compared with controls—is supported by our finding that such
mutations in these genes carries an odds ratio of 8.2 (95% CI 1–69)
in the PROMISSE study cohort. We replicated the association of
mutations in genes encoding complement inhibitors with pre-
eclampsia in a second cohort of patients with severe preeclampsia
and/or HELLP, but without underlying autoimmune disease.
Taken together, our results suggest that dysregulation of
complement activation can be a risk for preeclampsia.
Mutations in MCP and CFI appear to predispose to the
development of disease, and as observed in aHUS, mutations are
heterozygous and penetrance is incomplete [12]. In both
preeclampsia and aHUS, a second hit that initiates the
complement cascade or endothelial injury is required to manifest
disease. In PROMISSE Study patients, autoantibodies may lower
the threshold for preeclampsia, resulting in clinically apparent
disease. These autoantibodies trigger the classical pathway of
complement locally and systemically. Complement activation is
then amplified through the feedback loop of the alternative
pathway, leading to further injury of the placenta and stimulation
of endothelial cells to express a prothrombotic, proadhesive
phenotype (Figure 1). In patients with obesity or diabetes,
conditions that predispose to preeclampsia and are characterized
by systemic inflammation, the inflammatory process may sensitize
vascular endothelium to injury. In aHUS, infection or pregnancy
may trigger complement and precipitate disease [12,31]. Indeed,
in four patients with impaired complement regulatory protein
function, pregnancy precipitated thrombotic microangiopathy in
the form of atypical HELLP with severe renal involvement
[32,33]. Our findings in patients in the PROMISSE Study, taken
together with case series of aHUS and HELLP patients, argue that
pregnancy per se provokes or amplifies thrombotic microangiop-
athy in those already at risk due to inadequate control of the
complement system.
In sequencing only three complement regulatory genes, we
found heterozygous mutations in 10%–20% of PROMISSE
patients with preeclampsia, which likely underestimates the
importance of genetic defects in complement regulation, because
we analyzed only the maternal genes, although trophoblasts are of
fetal origin and express both maternal and paternal genes. Also,
we have yet to analyze CFB and C3, which account for 10%–15%
of the mutations in aHUS [13,15]. Our findings, in this
prospective, longitudinal study of patients at risk for preeclampsia
(in contrast to a biased sample from a case series), demonstrate that
mutations or uncommon variants in complement regulatory
proteins are not rare in those who develop disease and support
the possibility that they increase disease risk. Confirmation of the
presence of hypomorphic uncommon variants and mutations in a
cohort of non-autoimmune patients with severe preeclampsia (the
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PLoS Medicine | www.plosmedicine.org 6 March 2011 | Volume 8 | Issue 3 | e1001013Figure 2. C3b and C4b binding and cofactor activity of K32N compared to wild type MCP. (A) C4b and C3b binding. CHO cell lysates from
transient transfections were incubated with C4b- or C3b-coated wells and binding was assessed using a polyclonal antibody to MCP in an ELISA format.
CHO, a mock transfected control. Data represent the mean 6 standard deviation at each concentration from three independent experiments. (B)
Cofactor activity for CFI-mediated cleavage of C4b and C3b. Cell lysates containing 25 pg of MCP (wild-type or K32N) were incubated with biotinylated
C4b or C3bin the presence of purified humanCFI in 25 mM NaCl and cleavage was assessed by Western blot. C4bandC3b peptide chains andcleavage
fragments are identified. For C4b cofactor activity, C4d fragment generated by cleavage of C4b after 90 min was quantified by densitometric scanning,
compared with quantity of b chain, andnormalized to wild type. For C3bcofactor activity, a1 fragment generated by cleavage was compared to b chain
by densitometry, and normalized to wild type. Data represent the mean 6 standard deviation of three independent experiments. (C) Representative
Western blots of MCP activity for CFI-mediated cleavage of C4b and C3b. Left panel: MCP K32N has deficient C4b cofactor activity at 20 and 90 min. The
C4dfragmentgeneratedbycleavageofthea9chainisnotvisibleat20 minandisdiminishedrelativetowildtypeat90 min.Theboxedinsertsrepresent
5-fold longer exposure of the blot. The CHO negative control was a nonadjacent lane (broken line). Right panel: MCP K32N has similar C3b cofactor
activity to wild type. Equal amounts of a1 fragments are generated after 20 and90 min. TheCHO negative control was a nonadjacent lane (broken line).
In two additional experiments, similar results were obtained in cofactor assays at 150 mM NaCl concentration (unpublished data).
doi:10.1371/journal.pmed.1001013.g002
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complement activation in disease pathogenesis.
Based on findings in our patients and prior experiments in
mouse models, we propose the following mechanism for the
genesis of preeclampsia. Defective regulation of the complement
system allows for the excessive complement activation that leads to
placental damage, abnormal placental development, generalized
endothelial activation, and the release of antiangiogenic factors
toxic to the fenestrated endothelium of glomeruli, the choroid
plexus, and liver sinusoids—a sequence of events that culminates
in clinical preeclampsia (Figure 1). Future studies of the
PROMISSE cohort will determine whether elevations of split
products generated by activation of the alternative or classical
complement pathway predict preeclampsia in patients with APL
Ab and/or SLE, and the information in the current report will
allow us to refine these analyses and compare those with and
without mutations leading to excessive complement activation.
Our findings underscore the important role of complement
activation in preeclampsia, define mutations and likely mecha-
nisms for increased risk in patients with SLE and/or APL Ab, and
suggest new targets for treatment of this important public health
problem that, thus far, has defied reliable prediction and
satisfactory intervention.
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Background. Most pregnancies culminate in the birth of a
healthy baby but, sadly, about a quarter of women lose their
babies during pregnancy. A common pregnancy-related
medical problem that threatens the life of both baby and
mother is preeclampsia. Mild and severe preeclampsia affects
up to 10% and 1%–2% of pregnancies, respectively. Pree-
clampsia occurs because of a problem with the function of
the placenta, the organ that transfers nutrients and oxygen
from mother to baby and removes waste products from the
baby. Although preeclampsia begins early in pregnancy, it
is diagnosed by the onset of high blood pressure
(hypertension) and the appearance of protein in the urine
(proteinuria) after 20 weeks of pregnancy. Other warning signs
include headaches and swelling of the handsand face. The only
cure for preeclampsia is delivery, and labor is usually induced
early to prevent eclampsia (seizures), stroke, liver and kidney
failure, and breathing and blood vessel problemsdeveloping in
the mother. Although delivery before 37 weeks of pregnancy
is not generally recommended, in cases of preeclampsia it may
be too dangerous for both the baby and the mother to allow
the pregnancy to continue. Unfortunately when severe
preeclampsia occurs in the second trimester, babies weighing
only 500 grams may be delivered and they may not survive.
Why Was This Study Done? Because the exact cause of
preeclampsia is unknown, it is difficult to develop treatments
for the condition or to find ways to prevent it. Many experts
think that immune system problems—in particular, pertur-
bations in complement activation—may be involved in
preeclampsia. The complement system is a set of blood
proteins that attacks invading bacteria and viruses. The
activation of complement proteins is usually tightly regulated
(overactivation of the complement system causes tissue
damage) and, because preeclampsia may run in families, one
hypothesis is that mutations (genetic changes) in complement
regulatory proteins might predispose women to preeclampsia.
Inthisstudy, theresearcherstestthishypothesisbysequencing
genes encoding complement regulatory proteins in pregnant
women with the autoimmune diseases systemic lupus erythe-
matosus (SLE) and/or antiphospholipid antibodies (APL Ab)
who developed preeclampsia. In autoimmune diseases, the
immune system attacks healthy human cells instead of harmful
invaders. Both SLE and APL Ab are characterized by comple-
ment-mediated tissue injury and are associated with an
increased risk of preeclampsia and miscarriage.
What Did the Researchers Do and Find? Two hundred
fifty women with SLE and/or APL Ab were enrolled into the
PROMISSE study (a multi-center observational study to
identify predictors of pregnancy outcome in women with
SLE and/or APL Ab) when they were 12 weeks pregnant and
followed through pregnancy. Thirty patients developed
preeclampsia during the study and ten more had had
preeclampsia during a previous pregnancy. The researchers
sequenced the genes for complement regulatory proteins:
membrane cofactor protein (MCP), factor I, and factor H in
these 40 patients. Seven women (18%) had mutations in one
copy of one of these genes (there are two copies of most
genes in human cells). Five mutations were alterations in MCP
or factor I that are gene variants that increase the risk of
hemolytic uremic syndrome, a disease characterized by blood
vessel damage. The sixth mutation was a new MCP mutation
that impaired MCP’s ability to regulate complement
component C4b. The final mutation was a factor H mutation
that did not have any obvious functional effect. No mutations
in complement regulatory proteins were found in 34 matched
participants in PROMISSE without preeclampsia but, among a
group of non-autoimmune women who developed
preeclampsia during pregnancy, 10% had mutations in MCP
or factor I.
What Do These Findings Mean? These findings identify
MCP and factor I mutations as genetic defects associated
with preeclampsia in pregnant women with SLE and/or APL
Ab. Importantly, they also reveal an association between
similar mutations and preeclampsia in women without any
underlying autoimmune disease. Taken together with
evidence from previous animal experiments, these findings
suggest that dysregulation of complement activation is
involved in the development of preeclampsia. Although
further studies are needed to confirm and extend these
findings, these results suggest that proteins involved in the
regulation of complement activation could be new targets
for the treatment of preeclampsia and raise the possibility
that tests could be developed to identify women at risk of
developing preeclampsia.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001013.
N Tommy’s, a UK charity that funds scientific research into
the causes and prevention of miscarriage, premature birth,
and stillbirth, has information on preeclampsia
N The March of Dimes Foundation, a nonprofit organization
for pregnancy and baby health, has information on
preeclampsia
N The UK National Health Services Choices website also has
information about preeclampsia
N Wikipedia has pages on the complement system, on
autoimmune disease, and on preeclampsia (note that
Wikipedia is a free online encyclopedia that anyone can
edit; available in several languages)
N More information on the PROMISSE study is available
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